- TREMFYA® showed sustained inhibition of joint damage in psoriatic arthritis at 48 weeks.
- At Week 24, TREMFYA® was 2.5 times more effective than placebo in inhibiting joint damage.
- Placebo group switching to TREMFYA® at Week 24 saw a 57% reduction in radiographic progression by Week 48.
- ACR50 response rates improved from Week 24 to Week 48 in both dosing groups.
Study Overview
Johnson & Johnson's Phase 3b APEX study reveals that TREMFYA® effectively reduces signs and symptoms of active psoriatic arthritis (PsA) and inhibits structural joint damage over 48 weeks. The findings were presented at the Inflammatory Skin Disease Summit 2025.
Key Findings
At Week 24, TREMFYA® demonstrated a 2.5 times greater ability to inhibit joint structural damage compared to placebo, with consistent results for patients receiving doses every four or eight weeks. This inhibition was sustained through Week 48.
Placebo Group Results
Patients initially in the placebo group who switched to TREMFYA® at Week 24 experienced a 57% reduction in radiographic progression from baseline to Week 48, as measured by the PsA-modified van der Heijde-Sharp score.
Clinical Implications
Dr. Christopher Ritchlin from the University of Rochester Medical Center highlighted that TREMFYA® can inhibit joint damage progression, making it a valuable treatment for early intervention and for patients with existing joint damage.
Safety and Efficacy
TREMFYA® showed continued improvement in American College of Rheumatology response criteria (ACR50) rates from Week 24 to Week 48 in both dosing groups. Nearly half of the placebo group that transitioned to TREMFYA® achieved ACR50 by Week 48. The safety profile remained consistent with no new safety signals identified.
